

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

OMB APPROVAL
OMB Number: 3235-0076
Expires: April 30, 2008
Estimated average burden
hours per response....................... 16.00

141395

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

SEC USE ONLY				
Prefix	Scriel			
DATE RECEIVED				

Name of Official (Laborat 16th): is an associated and associate absociate absociate					
Name of Offering (check if this is an amendment and name has changed, and indicate change.) Mt. Cook Pharma, Inc. Common Stock and Warrant Financing					
Filing Under (Check box(cs) that apply): Rule 504 Rule 505 Rule 506	Section 4(6) ULOE				
Type of Filing: ☑ New Filing ☐ Amendment	2 string (6)				
	14411				
A. BASIC IDENTIFICATION DATA					
Enter the information requested about the issuer					
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)					
	07077548				
Mt. Cook Pharma, Inc.					
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)				
214 Carnegie Center, Princeton, New Jersey 08514	(609) 297-2185				
Address of Principal Business Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)				
(if different from Executive Offices)					
	PROCESSED				
Brief Description of Business	1 HOOESSED				
Manual and an anti-state of the state of the	DOT 0.2 com				
Developmental biotechnology company.					
Type of Business Organization ☐ corporation ☐ limited partnership, already formed ☐ other (please speci	IA): THOMASON.				
business trust limited partnership, to be formed	IN): THOMSON				
C sugarous and C sugarous because of the sugarous of the sugar	Month Year				
Actual or Estimated Date of Incorporation or Organization:	Actual Estimated				
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:					
CN for Canada; FN for other foreign jurisdiction	DE				

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation Q or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of manually signed copy or bear typed or pinted signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix in the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

SEC 1972 (6-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number:

A. BASIC IDENTIFIC	CATION DATA		
2. Enter the information requested for the following:	CATION DATA	<u> </u>	
Each promoter of the issuer, if the issuer has been organized visiting.	within the next five veem		
Each beneficial owner having the power to vote or dispose, or			more of a class of
 equity securities of the issuer; 	r afrect the vote or dispo-	siduti ot, 1076 ut	more of a class of
 Each executive officer and director of corporate issuers and o issuers; and 	f corporate general and n	nanaging partner	s of partnership
Each general and managing partner of partnership issuers.			
Check Box(es) that Apply: Promoter Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, if individual) Rosenwald, Lindsay A.	· · · · · · · · · · · · · · · · · · ·		
Business or Residence Address (Number and Street, City, State, Zip	Code		
c/o Paramount BioCapital, 787 7th Avenue, 48th Floor, New York, New York	rk. 10019		
Check Box(es) that Apply: Promoter Beneficial Owner		∑ Director	General and/or Managing Partner
Full Name (Last name first, if individual) Jostyn, Alan, Ph.D.			
Business or Residence Address (Number and Street, City, State, Zip	Code)	·	
c/o Mt. Cook Pharma, Inc., 214 Carnegle Center, Princeton, New Jersey			
Check Box(es) that Apply: Promoter Beneficial Owner	Executive Officer	Director	General and/or
Check Box(es) that Apply.	Executive Officer	M Director	Managing Partner
Full Name (Last name first, if individual)			
Nemeroff, Charles, MD			
Business or Residence Address (Number and Street, City, State, Zip			
c/o Mt. Cook Pharma, Inc., 214 Carnegie Center, Princeton, New Jersey			
Check Box(es) that Apply: Promoter Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual)			
Ellison, Russell, M.D.	0.13		
Business or Residence Address (Number and Street, City, State, Zip c/o Paramount BioCapital, Inc., 787 7th Avenue, 48th Floor, New York, Ne			
Check Box(es) that Apply: Promoter Beneficial Owner	Executive Officer	□ Director	General and/or
			Managing Partner
Full Name (Last name first, if individual) DiPietro, Daniel			
Business or Residence Address (Number and Street, City, State, Zip	Code)		
c/o Paramount BioCapital, Inc., 787 7th Avenue, 48th Floor, New York, Ne	w York 10019		
Check Box(es) that Apply: Promoter Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual)			
Hofer, Timothy			
Business or Residence Address (Number and Street, City, State, Zip			
c/o Paramount BioCapital, Inc., 787 7th Avenue, 48th Floor, New York, New		□ D !	CIO1 ''
Check Box(es) that Apply: Promoter Beneficial Owner	Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, if individual)			
Business or Residence Address (Number and Street, City, State, Zip	Code)		

B. INFORMATION ABOUT OFFERING No 1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? 冈 Answer also in Appendix, Column 2, if filing under ULOE. 2. What is the minimum investment that will be accepted from any individual?..... S N/A Νo 3. Does the offering permit joint ownership of a single unit? П 4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only. Full Name (Last name first, if individual) Paramount BioCapital, Inc. Business or Residence Address (Number and Street, City, State, Zlp Code) 787 7th Avenue, 48th Floor, New York, New York 10019 Name of Associated Broker or Dealer States in Which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States) All States [DE] [DC] [FL] [GA] [HI] [ID] [AL] [AR] [CA] [00] [CT] [AK] [AZ] [IL] [M] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO] NYI INCI MDI [OH] [OK] [OR] [NV] MJ MM [PA] [MT] (NE) NH [WI] [WY] [RI] [SC] [SD] [AV] [WA] [WV] (PR) [TN] Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code). Name of Associated Broker or Dealer States in Which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States) All States [AL] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI] [D] [AK] AZ [MN] [MS] [MO] [M] [Al] (KS) **(KY)** [LA] [ME] [MD] (MA) MI [MT] [NV] [NC] [MD] CHO [OR] [PA] MEI [NH] [NJ] [MM] [NY] [OK] m [VT] [VA] [WA] [WV] [WI] **(WY)** [PR] [RI] [SC] [SD] [TX] Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Name of Associated Broker or Dealer States in Which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)

All States [AL] [AK] [AZ] [AR] [CA] [CO] CTI (DE) [DC] (FL) [GA] UHII [[D]] [ובו] [N][KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO] [IA] [NC] [ND] [OH] [OK] [OR] [NE] INVI [NH] [NJ] [MM] [NY] [PA] (MT) [WV] [WI] [WY] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.) C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the insurer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. Transfer Agent's Fees Printing and Engraving Costs		\$
3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question I. Type of Offering Rule 505 Regulation A Rule 504 Total	Type of Security	Dollar Amount Sold \$ \$ \$ \$ \$ \$ \$ \$
Total (for filings under Rule 504 only) Answer also in Appendix, Column 4, if filing under ULOB.		s
Accredited Investors Non-accredited Investors	Number of Investors	Aggregate Dollar Amount of Purchases \$ 7,179,494.54 \$
2. Enter the number of accredited and non-accredited investors who have purchased accurities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased accurities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero".		
Answer also in Appendix, Column 3, if filing under ULOE.		
Convertible Securities (including warrants) Partnership Interests Other Total \$		\$ \$ \$ \$\$ 7,179,494.54
☑ Common ☐ Preferred		
Debt \$ Equity \$	40,000,000.00	\$ 7,179,494.54
this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. Type of Security	Aggregate Offering Price	Amount Aircady Sold

	C. OFFERING PRICE, NUM	iber of investors, expenses an	D US	È OF	PROCEE	DŚ	\$\$ \$\$ E
	b. Enter the difference between the aggregate offering 1 and total expenses furnished in response to Part C – gross proceeds to the issuer."	g price given in response to Part C – Question Question 4.a. This difference is the "adjusted				s ,	39,539,275.27
	Indicate below the amount of the adjusted gross proc for each of the purposes shown. If the amount for any check the box to the left of the estimate. The total or gross proceeds to the issuer set forth in response to Par	purpose is not known, furnish an estimate and fithe payments listed must equal the adjusted		Payme	ints to		
				Offic Directo Affili	eers, ors, & lates	_	Payments to Others
	Salaries and fees Purchase of real estate		H	· • -		님	2
	Purchase or real estate Purchase, rental or leasing and installation of mach	inen		• -		_	•
	and equipment			S			\$
	Construction or leasing of plant buildings and facil	litics	\Box	\$ -			\$
	Acquisition of other businesses (including the valu	e of securities involved in this		_			
	offering that may be used in exchange for the asset	ts or securities of another	_			_	_
	issuer pursuant to a merger)			\$ _		8	\$
	Repayment of indebtedness			· ž -		닖	2
	Working capital		님	\$ -		씜	\$ 39,539,275.27
	Other (specify):		H	•		H	\$
			H	Š		R	<u>; </u>
			_	-			
	Column Totals			\$_		X	\$ <u>39,539,275.27</u>
	Total Payments Listed (column totals added)				⊠ \$ <u>39</u>	539),275.27
	· 2000年1月1日 - 1000年1月1日 - 1000年1月1日 - 1000年1日	ALD TEDERAL SIGNATURE		護衛	阿勒拉勒 曼	Çğ la	跨河、建筑 等。
fo	ne issuer has duly caused this notice to be signed llowing signature constitutes an undertaking by quest of its staff, the information furnished by the	the issuer to furnish to the U.S. Securities	es ar	rd Exc	hange Con	mi	ssion, upon writte
le	suer (Print or Type)	Signature / //		Date	~1		
	t. Cook Pharma, Inc.	TIME MAN			ember	20	07
N	ame of Signer (Print or Type)	Title of Signer (Print or Type)					
	an Joslyn, Ph.D.	President and CEO /					

